Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial

[1]  N. Thatcher,et al.  Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma , 2005, British Journal of Cancer.

[2]  Yi-Chen Lin,et al.  Tumor-associated macrophages: the double-edged sword in cancer progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Atkins,et al.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Zeuthen,et al.  Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma , 2005, Cancer Immunology, Immunotherapy.

[5]  S. Hamilton-Dutoit,et al.  Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy , 2004, Clinical Cancer Research.

[6]  C. Lewis,et al.  Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. , 2004, Blood.

[7]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[8]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[9]  K. Hellstrand,et al.  Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis , 2004, Cancer Immunology, Immunotherapy.

[10]  R. Fisker,et al.  Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma , 2004, Cancer Immunology, Immunotherapy.

[11]  J. Pollard,et al.  Role of infiltrated leucocytes in tumour growth and spread , 2004, British Journal of Cancer.

[12]  K. Malmberg,et al.  Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? , 2004, Cancer immunology, immunotherapy : CII.

[13]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[14]  K. Hellstrand,et al.  Histamine Inhibits Neutrophil NADPH Oxidase Activity Triggered by the Lipoxin A4 Receptor‐Specific Peptide Agonist Trp‐Lys‐Tyr‐Met‐Val‐Met , 2003, Scandinavian journal of immunology.

[15]  S. Cuzzocrea,et al.  A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects , 2003, Nature Medicine.

[16]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[17]  H. Schmidt,et al.  A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma , 2002 .

[18]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  F. Nevens,et al.  A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon‐α‐2b for the treatment of chronic hepatitis C , 2002, Journal of viral hepatitis.

[20]  R. Fisker,et al.  Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival , 2002, British Journal of Cancer.

[21]  R. Herberman.  Cancer immunotherapy with natural killer cells. , 2002, Seminars in oncology.

[22]  K. Hellstrand.  Histamine in cancer immunotherapy: a preclinical background. , 2002, Seminars in oncology.

[23]  R. Henriksson,et al.  Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Kirkwood,et al.  Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Schmidt,et al.  A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  K J O'Byrne,et al.  Chronic immune activation and inflammation as the cause of malignancy , 2001, British Journal of Cancer.

[27]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[28]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[29]  L. Coussens,et al.  Inflammatory Cells and Cancer: Think Different! , 2001 .

[30]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[31]  U. Mellqvist,et al.  Histamine protects T cells and natural killer cells against oxidative stress. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[32]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  U. Mellqvist,et al.  Histamine dihydrochloride, interleukin-2 and interferon-α in multiple myeloma , 1999 .

[34]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[35]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[36]  P. Anderson,et al.  Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated cytotoxicity , 1996, European journal of immunology.

[37]  K. Hellstrand,et al.  Remission maintenance therapy with histamine and interleukin‐2 in acute myelogenous leukaemia , 1996, British journal of haematology.

[38]  K. Hellstrand,et al.  Histaminergic Regulation of Natural Killer Cell‐Mediated Clearance of Tumour Cells in Mice , 1996, Scandinavian journal of immunology.

[39]  E. Lopez Hänninen,et al.  Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. , 1996, The Journal of urology.

[40]  K. Hellstrand,et al.  Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. , 1996, Journal of immunology.

[41]  E. Tartour,et al.  Variable expression of CD3‐ζ chain in tumor‐infiltrating lymphocytes (TIL) derived from renal‐cell carcinoma: Relationship with til phenotype and function , 1995 .

[42]  K. Hellstrand,et al.  Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. , 1994, Journal of immunology.

[43]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[44]  K. Hellstrand,et al.  Role of histamine in natural killer cell-mediated resistance against tumor cells. , 1990, Journal of immunology.

[45]  K. Hellstrand,et al.  Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. , 1990, International archives of allergy and applied immunology.

[46]  H. J. G. GUNDERSEN,et al.  Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[47]  K. Hellstrand,et al.  Histamine H2-receptor-mediated regulation of human natural killer cell activity. , 1986, Journal of immunology.

[48]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[49]  Z. Werb,et al.  Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen. , 1982, The Journal of clinical investigation.

[50]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[51]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.